DrugPatentWatch Database Preview
Drugs in Development Information for Galactose
» See Plans and Pricing
What is the drug development status for Galactose?
Galactose is an investigational drug.
There have been 23 clinical trials for Galactose.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2012.
The most common disease conditions in clinical trials are Syndrome, Mucopolysaccharidosis IV, and Mucopolysaccharidoses. The leading clinical trial sponsors are BioMarin Pharmaceutical, University of Aarhus, and Northwell Health.
There is one US patent protecting this investigational drug and eighteen international patents.
Summary for Galactose
| US Patents | 1,595 |
| International Patents | 18,330 |
| US Patent Applications | 2,206 |
| WIPO Patent Applications | 2,693 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 3 (2012-09-01) |
| Vendors | 32 |
Recent Clinical Trials for Galactose
| Title | Sponsor | Phase |
|---|---|---|
| Intravenous Gene Transfer With an AAV9 Vector Expressing Human <=-Galactosidase in Type II GM1 Gangliosidosis | Axovant Sciences, Inc. | Phase 1/Phase 2 |
| Intravenous Gene Transfer With an AAV9 Vector Expressing Human <=-Galactosidase in Type II GM1 Gangliosidosis | National Human Genome Research Institute (NHGRI) | Phase 1/Phase 2 |
| Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia | Applied Therapeutics, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for Galactose
Top disease conditions for Galactose
Top clinical trial sponsors for Galactose
US Patents for Galactose
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Galactose | Start Trial | Small molecule ice recrystallization inhibitors and methods of use thereof | THE UNIVERSITY OF OTTAWA (Ottawa, CA) | Start Trial |
| Galactose | Start Trial | Methods and systems for growing plants using silicate-based substrates, cultivation of enhanced photosynthetic productivity and photosafening by utilization of exogenous glycopyranosides for endogenous glycopyranosyl-protein derivatives, and formulations, processes and systems for the same | Innovation Hammer, LLC (Powell, OH) | Start Trial |
| Galactose | Start Trial | Humanized anti-Tn-MUC1 antibodies and their conjugates | ADC Therpeutics S.A. (Epalinges, CH) Medimmune Limited (Cambridge, GB) | Start Trial |
| Galactose | Start Trial | Method for producing dopaminergic neurons | TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka-Shi, Osaka, JP) | Start Trial |
| Galactose | Start Trial | Probiotic Bifidobacterium adolescentis strains | CHR. Hansen A/S (Hoersholm, DK) | Start Trial |
| Galactose | Start Trial | Materials and methods for identifying and using yeast strains that metabolize pentose sugars in the presence of D-glucose | Indiana University Research and Technology Corporation (Indianapolis, IN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Galactose
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Galactose | Canada | CA2874501 | 2032-05-24 | Start Trial |
| Galactose | World Intellectual Property Organization (WIPO) | WO2013175299 | 2032-05-24 | Start Trial |
| Galactose | Australia | AU2012340849 | 2031-11-21 | Start Trial |
| Galactose | Australia | AU2017245459 | 2031-11-21 | Start Trial |
| Galactose | Brazil | BR112014012216 | 2031-11-21 | Start Trial |
| Galactose | Canada | CA2856580 | 2031-11-21 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
